Related references
Note: Only part of the references are listed.Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
Friederike Holze et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Yasmin Schmid et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
Friederike Holze et al.
NEUROPSYCHOPHARMACOLOGY (2021)
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies
Kristoffer A. A. Andersen et al.
ACTA PSYCHIATRICA SCANDINAVICA (2021)
Dose-response relationships of psilocybin-induced subjective experiences in humans
Tim Hirschfeld et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis
Patrick Vizeli et al.
SCIENTIFIC REPORTS (2021)
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Friederike Holze et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
Neiloufar Family et al.
PSYCHOPHARMACOLOGY (2020)
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
Nadia R. P. W. Hutten et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2020)
Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
Friederike Holze et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Effects of MDMA on attention to positive social cues and pleasantness of affective touch
Anya K. Bershad et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers
Anya K. Bershad et al.
BIOLOGICAL PSYCHIATRY (2019)
The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial
Steliana Yanakieva et al.
PSYCHOPHARMACOLOGY (2019)
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Theresa M. Carbonaro et al.
PSYCHOPHARMACOLOGY (2018)
Long-lasting subjective effects of LSD in normal subjects
Yasmin Schmid et al.
PSYCHOPHARMACOLOGY (2018)
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Leor Roseman et al.
FRONTIERS IN PHARMACOLOGY (2018)
Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
Giovanni Martinotti et al.
BRAIN SCIENCES (2018)
Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans
Andrea E. Steuer et al.
DRUG TESTING AND ANALYSIS (2017)
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Matthias E. Liechti et al.
PSYCHOPHARMACOLOGY (2017)
Safety pharmacology of acute MDMA administration in healthy subjects
Patrick Vizeli et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
Patrick C. Dolder et al.
CLINICAL PHARMACOKINETICS (2017)
Neuroticism is associated with challenging experiences with psilocybin mushrooms
Frederick S. Barrett et al.
PERSONALITY AND INDIVIDUAL DIFFERENCES (2017)
Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans
Patrick C. Dolder et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
Theresa M. Carbonaro et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology
Ido Hartogsohn
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Patrick C. Dolder et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Robin L. Carhart-Harris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review
Brian E. Grunau et al.
Canadian Journal of Emergency Medicine (2016)
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Yasmin Schmid et al.
BIOLOGICAL PSYCHIATRY (2015)
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
Peter Gasser et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
Peter Gasser et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2014)
MDMA enhances emotional empathy and prosocial behavior
Cedric M. Hysek et al.
SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE (2014)
Prediction of Psilocybin Response in Healthy Volunteers
Erich Studerus et al.
PLOS ONE (2012)
Duloxetine Inhibits Effects of MDMA (Ecstasy) In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study
Cedric M. Hysek et al.
PLOS ONE (2012)
Effects of the α2-Adrenergic Agonist Clonidine on the Pharmacodynamics and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Healthy Volunteers
Cedric M. Hysek et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Morbidity associated with MDMA (ecstasy) abuse: A survey of emergency department admissions
Pinchas Halpern et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2011)
Role of the norepinephrine uptake transporter in the mechanism of action of MDMA (Ecstasy)
C. M. Hysek et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2010)
Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)
Erich Studerus et al.
PLOS ONE (2010)
LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. A phase-II, double-blind, placebo-controlled dose-response pilot study
Torsten Passie et al.
CNS NEUROSCIENCE & THERAPEUTICS (2008)
Human hallucinogen research: guidelines for safety
M. W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
A review of the acute subjective effects of MDMA/ecstasy
Chelsea A. Baylen et al.
ADDICTION (2006)
3,4-methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: Psychomotor performance, subjective effects, and pharmacokinetics
C Hernandez-Lopez et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Share Paper
